LIVE
BMY
Bristol-Myers Squibb Company · Healthcare - Pharmaceuticals
$54.00
-7.39% this month
VERSUS
⟷
COMPARE
LLY
Eli Lilly and Company · Healthcare - Pharmaceuticals
$1,098.57
+7.55% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
BMY
2
LLY
3
Comparison scoreboard
LLY LEADS 3/5AI Score
BMY 40.3
LLY ✓73.6
1Y Return
BMY +14.33%
LLY ✓+38.84%
Fwd P/E
BMY ✓9.27
LLY 25.47
Target Up.
BMY ✓+10.41%
LLY +7.31%
Op. Margin
BMY 33.04%
LLY ✓49.39%
Metrics last refreshed: 6/20/2026
Quick take
BMY vs LLY Stock Comparison: AI Score, Valuation, Performance and Upside
BMY (Bristol-Myers Squibb) and LLY (Eli Lilly) are both major pharmaceutical companies but at very different market positions — Bristol-Myers Squibb is managing Revlimid revenue decline while growing Opdivo and rebuilding its pipeline, while Eli Lilly is experiencing an extraordinary commercial ramp of its GLP-1/GIP obesity and diabetes drugs that have made it one of the most valuable companies globally. BMS is the value/recovery story; Lilly is the growth story of the pharmaceutical decade.
BMY vs LLY is oncology/immunology portfolio navigating LOE headwinds (Bristol-Myers Squibb's Opdivo checkpoint inhibitor franchise and diversified pipeline working to offset Revlimid's patent cliff with Eliquis as the cash flow anchor) versus GLP-1 obesity and diabetes drug revolution (Eli Lilly's Mounjaro/Zepbound tirzepatide creating the pharmaceutical decade's biggest commercial opportunity in the massive global obesity treatment market) — value/pipeline recovery versus growth at extraordinary scale.
Live analysis · updated 6/20/2026
LLY holds the edge across 3 of 5 key metrics in this comparison. LLY has delivered stronger 1-year price return (+38.84% vs +14.33%), though BMY trades at the lower forward P/E (9.27x vs 25.47x). LLY leads on both revenue growth (55.50%) and operating margin (49.39%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BMY (+10.41%) than for LLY (+7.31%).
Normalized 1Y performance
BMY
LLY
Recent returns
BMY
LLY
Analyst price targets & sentiment
BMY · 22 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.7/5.0)
Price target range
analyst low$36.00
analyst high$68.00
analyst mean$63.08
current price$54.00
+10.4% upside to analyst mean
LLY · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.8/5.0)
Price target range
analyst low$650.00
analyst mean$1,215.79
current price$1,098.57
+7.3% upside to analyst mean
Who should consider this stock?
BMY may suit investors who:
- →Want a value-oriented large-cap pharmaceutical with Opdivo's established oncology franchise and Eliquis cash flows providing earnings support while the pipeline works to offset Revlimid headwinds
- →Value BMS's dividend and capital return as a pharma income stock whose current price may reflect the Revlimid discount more than future pipeline value
- →Believe BMS's diversified oncology pipeline (CAR-T, tyrosine kinase inhibitors, new cancer indications) will generate sufficient revenue to stabilize earnings after the Revlimid LOE period
LLY may suit investors who:
- →Want maximum exposure to the obesity and diabetes drug revolution — Lilly's Mounjaro/Zepbound franchise is the central holding for investors who believe GLP-1/GIP drugs represent a generational pharmaceutical opportunity
- →Value Lilly's best-in-class tirzepatide efficacy data as positioning it to capture premium market share in the massive obesity treatment market versus Novo Nordisk's competing products
- →Accept Lilly's very high valuation multiple as justified by the multi-decade market opportunity in obesity, which affects over 650 million adults globally, as the GLP-1 drug class expands into additional conditions
Performance & AI score
| Metric | BMY | LLY |
|---|---|---|
| AI score | 40.3 | 73.6 |
| AI rank | #1064 | #26 |
| Latest close | $54.00 | $1,098.57 |
| 1M return | -7.39% | +7.55% |
| 6M return | +0.84% | +5.45% |
| 1Y return | +14.33% | +38.84% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BMY | LLY |
|---|---|---|
| 1Y ago | $11.53K (+15.3%) started 2025-06-18 | $13.99K (+39.9%) started 2025-06-18 |
| 5Y ago | $11.08K (+10.8%) started 2021-06-21 | $53.49K (+434.9%) started 2021-06-21 |
| 10Y ago | $14.48K (+44.8%) started 2016-06-20 | $206.62K (+1966.2%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | BMY | LLY |
|---|---|---|
| Market cap | $116.66B | $1.01T |
| Trailing P/E | 16.00 | 40.32 |
| Forward P/E | 9.27 | 25.47 |
| Price/Sales | 2.07 | 14.10 |
| EV/Revenue | 3.15 | 14.51 |
| Analyst target | $63.08 | $1,215.79 |
| Target upside | +10.41% | +7.31% |
Growth, profitability & risk
| Metric | BMY | LLY |
|---|---|---|
| Revenue growth | 2.60% | 55.50% |
| Earnings growth | 9.20% | 169.90% |
| EPS growth | +9.20% | +169.90% |
| FCF margin | +20.32% | +12.67% |
| Operating margin | 33.04% | 49.39% |
| Profit margin | 15.01% | 34.99% |
| ROIC proxy | 38.73% | 107.46% |
| Return on equity | 38.73% | 107.46% |
| Dividend yield | 4.41% | 0.61% |
| Beta | 0.24 | 0.52 |
| Debt/equity | 230.97 | 139.01 |
| Current ratio | 1.42 | 1.50 |
| Quick ratio | 1.18 | 0.72 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
BMY max drawdown13.42%
LLY max drawdown23.31%
BMY max wkly drop11.50%
LLY max wkly drop17.93%
5Y risk snapshot
BMY max drawdown47.67%
LLY max drawdown34.48%
BMY max wkly drop11.78%
LLY max wkly drop17.93%
10Y risk snapshot
BMY max drawdown47.67%
LLY max drawdown34.48%
BMY max wkly drop20.86%
LLY max wkly drop17.93%
Performance metrics by period
| Period | Metric | BMY | LLY |
|---|---|---|---|
| 1Y | Growth | +15.29% | +39.94% |
| CAGR | +15.31% | +40.01% | |
| Sharpe ratio | 0.50 | 0.96 | |
| Max drawdown | 13.42% | 23.31% | |
| Max daily drop | 5.81% | 14.14% | |
| Max wkly drop | 11.50% | 17.93% | |
| 5Y | Growth | -5.92% | +413.56% |
| CAGR | -1.21% | +38.78% | |
| Sharpe ratio | -0.12 | 1.04 | |
| Max drawdown | 47.67% | 34.48% | |
| Max daily drop | 8.51% | 14.14% | |
| Max wkly drop | 11.78% | 17.93% | |
| 10Y | Growth | +2.48% | +1649.40% |
| CAGR | +0.25% | +33.16% | |
| Sharpe ratio | -0.04 | 0.95 | |
| Max drawdown | 47.67% | 34.48% | |
| Max daily drop | 15.99% | 14.14% | |
| Max wkly drop | 20.86% | 17.93% |
Business comparison
| Category | BMY | LLY |
|---|---|---|
| Company | Bristol-Myers Squibb Company | Eli Lilly and Company |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Bristol-Myers Squibb (BMS) is a global biopharmaceutical company specializing in oncology, hematology, and immunology — with key products including Opdivo (nivolumab, PD-1 checkpoint inhibitor for multiple cancers), Revlimid (lenalidomide, multiple myeloma, now facing generic competition), Eliquis (apixaban, blood thinner with Pfizer), Yervoy (ipilimumab, melanoma), Camzyos (cardiac myosin inhibitor), and Reblozyl (beta-thalassemia). BMS made major acquisitions including Celgene (2019) and Turning Point Therapeutics. | Eli Lilly is a global pharmaceutical company with the most commercially successful weight loss and diabetes drug franchise in history — Mounjaro (tirzepatide, type 2 diabetes), Zepbound (tirzepatide, obesity), Trulicity (dulaglutide, type 2 diabetes), and Verzenio (abemaciclib, breast cancer). Lilly's GLP-1/GIP dual agonist tirzepatide (Mounjaro/Zepbound) achieved unprecedented weight loss results (22.5% body weight reduction in clinical trials) and is transforming the pharmaceutical industry's market capitalization. |
| Investor focus | Investors track BMS's revenue trajectory as Revlimid loses patent protection (significant revenue loss from generic competition), the growth of Opdivo and newer oncology assets (Breyanzi CAR-T, Krazati), pipeline development across oncology and cardiovascular, and cost management as BMS navigates revenue headwinds from Revlimid loss of exclusivity. | Investors track Lilly's Mounjaro and Zepbound quarterly revenue growth, manufacturing capacity expansion to meet the massive GLP-1 demand surge, incretin class competitive dynamics with Novo Nordisk's semaglutide (Ozempic/Wegovy), pipeline readouts for oral GLP-1 and next-generation obesity drugs, and Lilly's valuation premium relative to pharmaceutical peers. |
BMY strengths
- →Opdivo checkpoint inhibitor franchise in multiple cancer indications — Opdivo has FDA approvals across 10+ cancer types (lung, kidney, bladder, melanoma, esophageal, gastric) and continues gaining new indications through ongoing clinical trials; the checkpoint inhibitor class remains a standard of care in oncology
- →Eliquis (with Pfizer) is a top-selling anticoagulant globally — Eliquis's revenue from the BMS/Pfizer partnership generates billions annually and has patent protection extending into the late 2020s, providing a durable cash flow stream
- →Diversified pipeline across oncology, cardiovascular, and immunology — BMS has multiple pipeline candidates that could generate meaningful revenue in the 2025-2030 timeframe to offset Revlimid headwinds
LLY strengths
- →Mounjaro/Zepbound dual GIP/GLP-1 agonist with best-in-class weight loss efficacy — tirzepatide's superior weight loss outcomes (22.5%) versus semaglutide's (~15%) in head-to-head data positions Lilly favorably versus Novo Nordisk's Wegovy in the massive obesity treatment market
- →Obesity market structural tailwind is potentially the largest pharmaceutical opportunity in history — approximately 650 million obese adults globally; obesity's links to diabetes, heart disease, sleep apnea, and cancer make effective treatment a major public health priority; GLP-1/GIP drugs are being studied in many adjacent conditions
- →Manufacturing capacity expansion to capture structural demand — Lilly is investing $6+ billion in new manufacturing facilities to meet demand for injectable and oral incretin drugs; this capacity build positions Lilly for years of supply-constrained revenue growth
Risks to watch — BMY
- →Revlimid LOE creates significant revenue headwind — Revlimid's loss of exclusivity (beginning 2022 in the U.S.) results in dramatic revenue decline as generic competition reduces market exclusivity; this headwind pressures BMS's total revenue for several years
- →Execution risk on pipeline to offset Revlimid — BMS needs multiple pipeline successes to replace Revlimid revenue; pipeline failures or competitive losses in key oncology indications would be materially negative
- →Opdivo competition from newer checkpoint inhibitors — Keytruda (Merck's pembrolizumab) has become the dominant PD-1 inhibitor in most cancers, gaining market share from Opdivo; BMS must differentiate Opdivo through specific combination regimens and biomarker-selected patient populations
Risks to watch — LLY
- →Manufacturing capacity is the near-term constraint on revenue — demand for Mounjaro and Zepbound significantly exceeds Lilly's production capacity; inability to meet demand cedes market share to Novo Nordisk and delays peak revenue realization
- →Novo Nordisk semaglutide competition — Ozempic (diabetes) and Wegovy (obesity) remain the market leaders; Novo Nordisk's competitive response and pricing may limit Lilly's market share expansion
- →Oral GLP-1 race is critical for long-term market expansion — injectable GLP-1 drugs limit adoption among patients preferring oral medications; Lilly's oral GLP-1 (orforglipron) and Novo's oral semaglutide are competing for a potentially massive oral obesity treatment market
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →